Report from the 67th Annual Meeting of the American Academy of Dermatology

British Journal of Dermatology

Volumn 162, Issue 1, 2010, Pages 12-21

  Alexandroff, A B ^a   Graham Brown, R A C ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Atherosclerosis; Community acquired methicillin resistant Staphylococcus aureus; Dermoscopy; Melanoma; Psoriasis

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AN 2728; AN 2898; ANTIPSORIASIS AGENT; BORTEZOMIB; CLINDAMYCIN; CORTICOSTEROID DERIVATIVE; DOXYCYCLINE; EFALIZUMAB; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETANERCEPT; FUSIDATE SODIUM; GABAPENTIN; GEFITINIB; IMATINIB; INCB 018424; ISOTRETINOIN; METHOTREXATE; MINOCYCLINE; PREGABALIN; RAPAMYCIN; RETINOID DERIVATIVE; RIFAMPICIN; SORAFENIB; SUNSCREEN; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ACNE; ADVERSE OUTCOME; ALLOPATHY; ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; ATOPIC DERMATITIS; BASAL CELL CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CELLULITIS; CLINICAL RESEARCH; COLON CARCINOMA; CONFERENCE PAPER; DISEASE CONTROL; DRUG ERUPTION; DRUG WITHDRAWAL; EPILUMINESCENCE MICROSCOPY; FOLLICULITIS; HEAD AND NECK CARCINOMA; HUMAN; HYPERHIDROSIS; LOW DRUG DOSE; LUNG CARCINOMA; MEDICAL EDUCATION; MELANOMA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEVUS; NONHODGKIN LYMPHOMA; PANCREAS CARCINOMA; PARONYCHIA; PHOTOTHERAPY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; RASH; RHEUMATOID ARTHRITIS; SKIN DISEASE; SKIN EDEMA; SQUAMOUS CELL CARCINOMA; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

ANTINEOPLASTIC AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DERMATOLOGY; DERMOSCOPY; ESTHETICS; HUMANS; MELANOMA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NEVUS; PSORIASIS; SAN FRANCISCO; SKIN NEOPLASMS; SOCIETIES, MEDICAL; STAPHYLOCOCCAL INFECTIONS;

EID: 72749108219     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09395.x     Document Type: Conference Paper

References (262)

1. Nowecki ZI, Rutkowski P, Kulik J et al. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Br J Dermatol 2008 159 : 597 605.
2. Green DS, Dalgleish AG, Belonwu N et al. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 2008 159 : 606 614.
3. Green DS, Bodman-Smith MD, Dalgleish AG et al. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007 156 : 337 345.
4. Vestergaard ME, Macaskill P, Holt PE et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008 159 : 669 676.
5. Guitera P, Li LX, Crotty K et al. Melanoma histological Breslow thickness predicted by 75-MHz ultrasonography. Br J Dermatol 2008 159 : 364 369.
6. Bories N, Dalle S, Debarbieux S et al. Dermoscopy of fully regressive cutaneous melanoma. Br J Dermatol 2008 158 : 1224 1229.
7. Debarbieux S, Ronger-Salve S, Dalle S et al. Dermoscopy of desmoplastic melanoma: report of six cases. Br J Dermatol 2008 159 : 360 363.
8. Debarbieux S, Duru G, Dalle S et al. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol 2007 157 : 58 67.
9. Pfohler C, Schmaltz R, Graeber S et al. 'Autoimmunity' is not always associated with prolonged survival in melanoma patients. Br J Dermatol 2008 159 : 735 736.
10. Einwachter-Thompson J, MacKie RM. An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis. Br J Dermatol 2008 159 : 337 341.
11. Argenziano G, Mordente I, Ferrara G et al. Dermoscopic monitoring of melanocytic skin lesions: clinical outcome and patient compliance vary according to follow-up protocols. Br J Dermatol 2008 159 : 331 336.
12. Gerger A, Hofmann-Wellenhof R, Langsenlehner U et al. In vivo confocal laser scanning microscopy of melanocytic skin tumours: diagnostic applicability using unselected tumour images. Br J Dermatol 2008 158 : 329 333.
13. Lipoff JB, Scope A, Dusza SW et al. Complex dermoscopic pattern: a potential risk marker for melanoma. Br J Dermatol 2008 158 : 821 824.
14. Hall PN, Hunter JE, Walter FM et al. Use of a spectrophotometric intracutaneous analysis device in the real-time diagnosis of melanoma. Br J Dermatol 2008 158 : 420 421.
15. Tao J, Li Y, Liu YQ et al. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors. Br J Dermatol 2008 158 : 88 94.
16. Tucci MG, Lucarini G, Brancorsini D et al. Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 2007 157 : 1212 1216.
17. Perrinaud A, Gaide O, French LE et al. Can automated dermoscopy image analysis instruments provide added benefit for the dermatologist? A study comparing the results of three systems Br J Dermatol 2007 157 : 926 933.
18. Braun RP, Gaide O, Oliviero M et al. The significance of multiple blue-grey dots (granularity) for the dermoscopic diagnosis of melanoma. Br J Dermatol 2007 157 : 907 913.
19. Strauss RM, Elliott F, Affleck P et al. A retrospective study addressed to understanding what predicts severe histological dysplasia/early melanoma in excised atypical melanocytic lesions. Br J Dermatol 2007 157 : 758 764.
20. Diffey B. Sunbeds, beauty and melanoma. Br J Dermatol 2007 157 : 215 216.
21. Lipsker D, Engel F, Cribier B et al. Trends in melanoma epidemiology suggest three different types of melanoma. Br J Dermatol 2007 157 : 338 343.
22. Phan A, Touzet S, Dalle S et al. Acral lentiginous melanoma: histopathological prognostic features of 121 cases. Br J Dermatol 2007 157 : 311 318.
23. Calista D. Treatment of lentigo maligna with topical 1% cidofovir. Br J Dermatol 2007 157 : 421 423.
24. Vercambre-Darras S, Dubucquoi S, Fajardy I et al. Does spontaneous autoimmunity improve survival in visceral metastatic melanoma? Br J Dermatol 2007 157 : 413 415.
25. Haniffa MA, Lloyd JJ, Lawrence CM. The use of a spectrophotometric intracutaneous analysis device in the real-time diagnosis of melanoma in the setting of a melanoma screening clinic. Br J Dermatol 2007 156 : 1350 1352.
26. Weatherhead SC, Haniffa M, Lawrence CM. Melanomas arising from naevi and de novo melanomas: does origin matter? Br J Dermatol 2007 156 : 72 6.
27. Takata M, Lin J, Takayanagi S et al. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and Spitzoid lesion. Br J Dermatol 2007 156 : 1287 1294.
28. Vitzthum J, Dorr HD, Meineke V. Ultraviolet B exposure could influence the interpretation of serum S100beta levels in patients with malignant melanoma. Br J Dermatol 2007 156 : 772 773.
29. Kawasaki K, Kawakami T, Watabe H et al. Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma. Br J Dermatol 2007 156 : 613 619.
30. Meier F, Busch S, Lasithiotakis K et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007 156 : 1204 1213.
31. Baumert J, Plewig G, Volkenandt M et al. Factors associated with a high tumour thickness in patients with melanoma. Br J Dermatol 2007 156 : 938 944.
32. Fearfield LA, Larkin JM, Rowe A et al. Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma. Br J Dermatol 2007 156 : 440 447.
33. Stefanaki I, Stratigos AJ, Dimisianos G et al. p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. Br J Dermatol 2007 156 : 357 362.
34. Brown VL, Matin RN, Cerio R et al. Melanomas in renal transplant recipients: the London experience, and invitation to participate in a European study. Br J Dermatol 2007 156 : 165 167.
35. Odenbro A, Gillgren P, Bellocco R et al. The risk for cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma in relation to tobacco use and body mass index. Br J Dermatol 2007 156 : 99 105.
36. Singh M, Lin J, Hocker TL et al. Genetics of melanoma tumorigenesis. Br J Dermatol 2008 158 : 15 21.
37. Boulaiz H, Prados J, Melguizo C et al. Tumour malignancy loss and cell differentiation are associated with induction of gef gene in human melanoma cells. Br J Dermatol 2008 159 : 370 378.
38. Lin J, Hocker TL, Singh M et al. Genetics of melanoma predisposition. Br J Dermatol 2008 159 : 286 291.
39. Sini MC, Manca A, Cossu A et al. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. Br J Dermatol 2008 158 : 243 250.
40. Alexandroff AB, Gibbs S. Skin deep: report from the annual meeting of the British Society for Investigative Dermatology. Exp Oncol 2007 29 : 162 163.
41. Muchemwa FC, Ma D, Inoue Y et al. Constitutive activation of the phosphatidyl inositol 3 kinase signalling pathway in acral lentiginous melanoma. Br J Dermatol 2008 158 : 411 413.
42. Alexandroff AB, Jackson AM, Paterson T et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000 37 : 515 526.
43. Da Forno PD, Fletcher A, Pringle JH et al. Understanding Spitzoid tumours: new insights from molecular pathology. Br J Dermatol 2008 158 : 4 14.
44. Alexandroff AB, Da Forno PD, Johnston GA. Lack of significance of sentinel lymph node biopsy for the prognosis and management of the atypical Spitz tumor of uncertain biologic potential. Expert Rev Dermatol 2009 (in press).
45. Lugassy C, Kleinman HK, Vernon SE et al. C16 laminin peptide increases angiotropic extravascular migration of human melanoma cells in a shell-less chick chorioallantoic membrane assay. Br J Dermatol 2007 157 : 780 782.
46. Alexandroff AB, Robins RA, Murray A et al. Tumour immunology: false hopes - new horizons? Immunol Today 1998 19 : 247 250.
47. Alexandroff AB, McIntyre CA, Porter JC et al. Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer. Br J Cancer 1998 77 : 1806 1811.
48. Alexandroff AB. Once more unto the breach. Inaugural meeting of the British Society for Immunology Tumour Immunology Affinity Group. Cancer Immunol Immunother 1996 43 : 254 255.
49. Alexandroff AB, Dalgleish AG. Cancer biologists hit the road. Molecular genetics of cancer: Second Joint Conference of the American Association for Cancer Research and the European Association for Cancer Research. Oxford, U.K., 9-13 September 1997. Cancer gene therapy symposium. London, U.K., 23-24 June 1997. Mol Med Today 1997 3 : 524 527.
50. Argenziano G, Zalaudek I, Ferrara G et al. Proposal of a new classification system for melanocytic naevi. Br J Dermatol 2007 157 : 217 227.
51. Kinsler VA, Chong WK, Aylett SE et al. Complications of congenital melanocytic naevi in children: analysis of 16 years' experience and clinical practice. Br J Dermatol 2008 159 : 907 914.
52. Ahlgrimm-Siess V, Massone C, Koller S et al. In vivo confocal scanning laser microscopy of common naevi with globular, homogeneous and reticular pattern in dermoscopy. Br J Dermatol 2008 158 : 1000 1007.
53. West EA, McPartland JL, Rigby H et al. Giant bathing trunk naevus with lymphadenopathy and unusual pathology. Br J Dermatol 2007 157 : 599 601.
54. Kishi K, Matsuda N, Kubota Y et al. Rapid, severe repigmentation of congenital melanocytic naevi after curettage and dermabrasion: histological features. Br J Dermatol 2007 156 : 1251 1257.
55. Kinsler VA, Birley J, Atherton DJ. Great Ormond Street Hospital for Children Registry for Congenital Melanocytic Naevi: prospective study 1988-2007. Part 1 - epidemiology, phenotype and outcomes. Br J Dermatol 2009 160 : 143 150.
56. Kinsler VA, Birley J, Atherton DJ. Great Ormond Street Hospital for Children Registry for Congenital Melanocytic Naevi: prospective study 1988-2007. Part 2 - evaluation of treatments. Br J Dermatol 2009 160 : 387 392.
57. Gallus S, Naldi L. Distribution of congenital melanocytic naevi and congenital naevus-like naevi in a survey of 3406 Italian schoolchildren. Br J Dermatol 2008 159 : 433 438.
58. Mourmouras V, Fimiani M, Rubegni P et al. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. Br J Dermatol 2007 157 : 531 539.
59. Ponnampalam J, Nicholson J, Atherton D. Leptomeningeal melanoma and multiple cutaneous melanocytic naevi. Br J Dermatol 2007 157 : 397 398.
60. Zalaudek I, Grinschgl S, Argenziano G et al. Age-related prevalence of dermoscopy patterns in acquired melanocytic naevi. Br J Dermatol 2006 154 : 299 304.
61. Scope A, Marghoob AA, Dusza SW et al. Dermoscopic patterns of naevi in fifth grade children of the Framingham school system. Br J Dermatol 2008 158 : 1041 1049.
62. Menzies SW, Gutenev A, Avramidis M et al. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol 2001 137 : 1583 1589.
63. Curtin JA, Busam K, Pinkel D et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006 24 : 4340 4346.
64. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005 353 : 2135 2147.
65. Lacouture ME, Lai SE. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006 155 : 852 854.
66. Zoller A, Schad SG, Gross GE. Erlotinib-associated skin reactions: case report and proposal for classification. Br J Dermatol 2006 155 : 1293 1295.
67. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 354 : 567 578.
68. Muller H, Eisendle K, Gastl G et al. Palliative therapy of giant basal cell carcinoma with the monoclonal antiepidermal growth factor receptor antibody cetuximab. Br J Dermatol 2008 158 : 1386 1388.
69. Wierzbicka E, Tourani JM, Guillet G. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol 2006 155 : 213 214.
70. Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy Oncologist 2008 13 : 1201 1204.
71. Jatoi A, Rowland K, Sloan JA et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008 113 : 847 853.
72. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009 373 : 1525 1531.
73. Dudek AZ, Kmak KL, Koopmeiners J et al. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 2006 51 : 89 96.
74. Orditura M, De VF, Galizia G et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep 2009 21 : 1023 1028.
75. Kullmann F, Hollerbach S, Dollinger MM et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 2009 100 : 1032 1036.
76. Bauer KA, Hammerman S, Rapoport B et al. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. Clin Colorectal Cancer 2008 7 : 309 314.
77. Shu KY, Kindler HL, Medenica M et al. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 2006 154 : 191 192.
78. Porzio G, Aielli F, Verna L et al. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage 2006 32 : 397 398.
79. Gerecitano J, Goy A, Wright J et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006 134 : 391 398.
80. Berth-Jones J, Thompson J, Papp K. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008 159 : 407 412.
81. Henno A, Blacher S, Lambert C et al. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis. Br J Dermatol 2009 160 : 581 590.
82. Stenderup K, Rosada C, Worsaae A et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2008 160 : 284 296.
83. Lloyd A, Reeves P, Conway P et al. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol 2009 160 : 380 386.
84. Thaci D. Long-term data in the treatment of psoriasis. Br J Dermatol 2008 159 (Suppl. 2 18 24.
85. Samoud-El KS, Galai Y, Sghiri R et al. BAFF is elevated in serum of patients with psoriasis: association with disease activity. Br J Dermatol 2008 159 : 765 768.
86. Feldman SR, Gottlieb AB, Bala M et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008 159 : 704 710.
87. Lecluse LL, Piskin G, Mekkes JR et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008 159 : 527 536.
88. Driessen RJ, de Jong EM, de Rie MA et al. Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis. Br J Dermatol 2008 159 : 760 761.
89. Wakkee M, Lugtenberg M, Spuls PI et al. Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists. Br J Dermatol 2008 159 : 426 432.
90. Rigopoulos D, Gregoriou S, Stratigos A et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008 159 : 453 456.
91. Cronin JG, Mesher D, Purdie K et al. Beta-papillomaviruses and psoriasis: an intrapatient comparison of human papillomavirus carriage in skin and hair. Br J Dermatol 2008 159 : 113 119.
92. Strober B, Teller C, Yamauchi P et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008 159 : 322 330.
93. Nijsten T, Spuls PI. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis. Br J Dermatol 2008 159 : 257 258.
94. Fiedler E, Helmbold P, Marsch WC. Increased vessel density in psoriasis: involvement of lymphatic vessels in the papillary dermis. Br J Dermatol 2008 159 : 258 261.
95. van Lingen RG, Korver JE, van de Kerkhof PC et al. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies. Br J Dermatol 2008 159 : 91 6.
96. Simon M, Tazi-Ahnini R, Jonca N et al. Alterations in the desquamation-related proteolytic cleavage of corneodesmosin and other corneodesmosomal proteins in psoriatic lesional epidermis. Br J Dermatol 2008 159 : 77 85.
97. van Lingen RG, van de Kerkhof PC, Seyger MM et al. CD26/dipeptidyl- peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol 2008 158 : 1264 1272.
98. Chen M, Chen ZQ, Cui PG et al. The methylation pattern of p16INK4a gene promoter in psoriatic epidermis and its clinical significance. Br J Dermatol 2008 158 : 987 993.
99. Farkas A, Tonel G, Nestle FO. Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol 2008 158 : 921 929.
100. Oh ST, Schramme A, Stark A et al. Overexpression of ADAM 10 and ADAM 12 in lesional psoriatic skin. Br J Dermatol 2008 158 : 1371 1373.
101. Fujimura T, Okuyama R, Ito Y et al. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides. Br J Dermatol 2008 158 : 1256 1263.
102. Smith RL, Warren RB, Eyre S et al. Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. Br J Dermatol 2008 158 : 962 968.
103. Vissers WH, van Vlijmen I, van Erp PE et al. Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. Br J Dermatol 2008 158 : 705 712.
104. Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC et al. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol 2008 158 : 1146 1148.
105. Ormerod AD. Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. Br J Dermatol 2008 158 : 435 436.
106. Sun LD, Yang S, Liu JJ et al. Follow-up analysis of 180 Chinese Han families: identification of a novel locus for psoriasis at 2p22.3-11.2. Br J Dermatol 2008 158 : 512 517.
107. Collin B, Srinathan SK, Finch TM. Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists. Br J Dermatol 2008 158 : 793 800.
108. Ardern-Jones MR, Black AP, Ogg GS. Antilymphocyte function associated antigen-1 inhibits T-helper 2 function of human allergen-specific CD4+ T cells. Br J Dermatol 2008 158 : 456 462.
109. Liu X, Lin J, Wang L et al. Telomerase activity in peripheral blood mononuclear cells of psoriatic patients correlates with disease severity. Br J Dermatol 2008 158 : 637 639.
110. Sergeant A, Makrygeorgou A, Chan WC et al. C-reactive protein in psoriasis. Br J Dermatol 2008 158 : 417 419.
111. de Korte J, van der Valk PG, Sprangers MA et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. Br J Dermatol 2008 158 : 375 381.
112. Woods AL, Rutter KJ, Gardner LS et al. Inpatient management of psoriasis: a multicentre service review to establish national admission standards. Br J Dermatol 2008 158 : 266 272.
113. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158 : 558 566.
114. Revicki D, Willian MK, Saurat JH et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008 158 : 549 557.
115. Christophers E. Explaining phenotype heterogeneity in patients with psoriasis. Br J Dermatol 2008 158 : 437 441.
116. Teraki Y, Fukuda T. Pemphigoid nodularis associated with psoriatic erythroderma: successful treatment with suplatast tosilate. Br J Dermatol 2008 158 : 424 426.
117. Kirby B, Richards HL, Mason DL et al. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008 158 : 138 140.
118. Flytstrom I, Stenberg B, Svensson A et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008 158 : 116 121.
119. -1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007 157 : 1005 1012.
120. Hampton PJ, Ross OK, Reynolds NJ. Increased nuclear beta-catenin in suprabasal involved psoriatic epidermis. Br J Dermatol 2007 157 : 1168 1177.
121. Campanati A, Goteri G, Simonetti O et al. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br J Dermatol 2007 157 : 1155 1160.
122. Krishnan R, Cella D, Leonardi C et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007 157 : 1275 1277.
123. Smith G, Wilkie MJ, Deeni YY et al. Melanocortin 1 receptor (MC1R) genotype influences erythemal sensitivity to psoralen-ultraviolet A photochemotherapy. Br J Dermatol 2007 157 : 1230 1234.
124. Cowen EW, Liu CW, Steinberg SM et al. Differentiation of tumour-stage mycosis fungoides, psoriasis vulgaris and normal controls in a pilot study using serum proteomic analysis. Br J Dermatol 2007 157 : 946 953.
125. Ciocon DH, Kimball AB. Psoriasis and psoriatic arthritis: separate or one and the same? Br J Dermatol 2007 157 : 850 860.
126. Guttman-Yassky E, Krueger JG. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007 157 : 1103 1115.
127. Nograles KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008 159 : 1092 1102.
128. Takahashi MD, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol 2007 157 : 828 831.
129. Takahata Y, Sugita T, Hiruma M et al. Quantitative analysis of Malassezia in the scale of patients with psoriasis using a real-time polymerase chain reaction assay. Br J Dermatol 2007 157 : 670 673.
130. Moles JP, Tesniere A, Guilhou JJ. Reverse transcriptase activity in human normal and psoriatic skin samples. Br J Dermatol 2007 157 : 482 486.
131. Watabe D, Kanno H, Yoshida A et al. Adhesion of peripheral blood mononuclear cells and CD4+ T cells from patients with psoriasis to cultured endothelial cells via the interaction between lymphocyte function-associated antigen type 1 and intercellular adhesion molecule 1. Br J Dermatol 2007 157 : 259 265.
132. Wachter T, Murach WM, Brocker EB et al. Recalcitrant lithium-induced psoriasis in a suicidal patient alleviated by tumour necrosis factor-alpha inhibition. Br J Dermatol 2007 157 : 627 629.
133. Rott S, Kuster RM, Mrowietz U. Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko. Br J Dermatol 2007 157 : 191 192.
134. Hoffjan S, Stemmler S. On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol 2007 157 : 441 449.
135. Costanzo A, Papoutsaki M, Mazzotta A et al. Consecutive use of different biological therapies in the treatment of psoriasis. Br J Dermatol 2007 157 : 394.
136. Nedoszytko B, Szczerkowska-Dobosz A, Zablotna M et al. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol 2007 157 : 165 167.
137. Altobelli E, Petrocelli R, Marziliano C et al. Family history of psoriasis and age at disease onset in Italian patients with psoriasis. Br J Dermatol 2007 156 : 1400 1401.
138. Chang SE, Han SS, Jung HJ et al. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol 2007 156 : 1272 1277.
139. Bedini C, Nasorri F, Girolomoni G et al. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol 2007 157 : 249 258.
140. Hern S, Mortimer PS. In vivo quantification of microvessels in clinically uninvolved psoriatic skin and in normal skin. Br J Dermatol 2007 156 : 1224 1229.
141. Komatsu N, Saijoh K, Kuk C et al. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Br J Dermatol 2007 156 : 875 883.
142. Katugampola RP, Hughes TM, Mills CM et al. Allergic contact dermatitis complicating pustular psoriasis in two patients. Br J Dermatol 2007 156 : 788 790.
143. Chang YT, Chou CT, Yu CW et al. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol 2007 156 : 899 905.
144. Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol 2007 156 : 838 842.
145. Peltonen S, Riehokainen J, Pummi K et al. Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis. Br J Dermatol 2007 156 : 466 472.
146. Birnie A, Langan S, English JS. Updates from the British Association of Dermatologists 87th annual meeting, 10-13 July 2007, Birmingham, U.K. Br J Dermatol 2008 158 : 1182 1188.
147. Birnie A, Langan S, English JS et al. Updates from the British Association of Dermatologists 86th annual meeting, 4-7 July 2006, Manchester, U.K. Br J Dermatol 2007 156 : 802 813.
148. Chang YC, Wu WM, Chen CH et al. Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan. Br J Dermatol 2007 156 : 642 645.
149. Michaelsson G, Kristjansson G, Pihl Lundin I et al. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol 2007 156 : 659 666.
150. Kingo K, Mossner R, Koks S et al. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol 2007 156 : 646 652.
151. Hubiche T, Leaute-Labreze C, Lepreux S et al. Psoriasis after cord blood stem cell transplantation. Br J Dermatol 2007 156 : 386 388.
152. Frigerio E, Colombo MD, Franchi C et al. Severe psoriasis treated with a new macrolide: everolimus. Br J Dermatol 2007 156 : 372 374.
153. Hochberg M, Zeligson S, Amariglio N et al. Genomic-scale analysis of psoriatic skin reveals differentially expressed insulin-like growth factor-binding protein-7 after phototherapy. Br J Dermatol 2007 156 : 289 300.
154. Bovenschen HJ, Otero ME, Langewouters AM et al. Oral retinoic acid metabolism blocking agent Rambazole for plaque psoriasis: an immunohistochemical study. Br J Dermatol 2007 156 : 263 270.
155. Griffiths CE, Christophers E, Barker JN et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007 156 : 258 262.
156. Harrison CA, Layton CM, Hau Z et al. Transglutaminase inhibitors induce hyperproliferation and parakeratosis in tissue-engineered skin. Br J Dermatol 2007 156 : 247 257.
157. Korver JE, Vissers WH, van Rens DW et al. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. Br J Dermatol 2007 156 : 130 137.
158. Simonart T, Heenen M. T cell/keratinocyte interactions in psoriasis: where is the trigger? Br J Dermatol 2007 156 : 171 172.
159. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007 156 : 945 950.
160. Schmitt J, Zhang Z, Wozel G et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008 159 : 513 526.
161. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 371 : 1675 1684.
162. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 371 : 1665 1674.
163. Shaw J, Liu C, Martin R et al. Inhibition of tumour necrosis factor-alpha secretion from EpiDermTM tissues by a novel small molecule, UTL-5d. Br J Dermatol 2007 157 : 575 579.
164. Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol 2008 159 : 460 463.
165. Jacobi A, Schuler G, Hertl M. Differential clinical response to alefacept in combination with methotrexate in two patients with refractory palmar psoriasis. Br J Dermatol 2007 156 : 178 180.
166. Selenko-Gebauer N, Karlhofer F, Stingl G. Efalizumab in routine use: a clinical experience. Br J Dermatol 2007 156 (Suppl. 2 1 6.
167. Warren RB, Brown BC, Lavery D et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009 160 : 162 169.
168. Mavilia L, Mori M, Rossi R et al. 308 nm monochromatic excimer light in dermatology: personal experience and review of the literature. G Ital Dermatol Venereol 2008 143 : 329 337.
169. Morison WL, Atkinson DF, Werthman L. Effective treatment of scalp psoriasis using the excimer (308 nm) laser. Photodermatol Photoimmunol Photomed 2006 22 : 181 183.
170. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988 91 : 120 124.
171. McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 1973 288 : 912.
172. Alexandroff AB, Pauriah M, Camp RD et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009 Jun 4 [Epub ahead of print].
173. Wakkee M, Thio HB, Prens EP et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007 190 : 1 9.
174. Katsambas A. Treating psoriasis as a chronic inflammatory systemic disease. Br J Dermatol 2008 159 (Suppl. 2 1.
175. Kaur S, Zilmer K, Kairane C et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008 159 : 1364 1367.
176. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007 157 : 649 655.
177. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007 25 : 529 534.
178. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995 32 : 982 986.
179. Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 298 : 321 328.
180. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 1741.
181. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008 159 : 895 902.
182. Friedewald VE, Cather JC, Gelfand JM et al. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008 102 : 1631 1643.
183. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008 159 : 1331 1337.
184. Brauchli YB, Jick SS, Miret M et al. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009 160 : 1048 1056.
185. Gisondi P, Tessari G, Conti A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007 157 : 68 73.
186. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008 159 (Suppl. 2 2 9.
187. Alexandroff AB, Burd R. Footprints of the EADV: a meeting report from the 17th Congress of the European Academy of Dermatology and Venereology. Br J Dermatol 2009 160 : 938 945.
188. Zadrazil J, Tichy T, Horak P et al. IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of 'psoriatic nephropathy'. J Nephrol 2006 19 : 382 386.
189. Jiao Y, Xu H, Li H et al. Mesangial proliferative glomerulonephritis with or without IgA deposits: the morphological characters in psoriasis vulgaris. Nephron Clin Pract 2008 108 : c221 5.
190. Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity? Am J Ophthalmol 2005 139 : 106 111.
191. Friedlaender M. Ocular findings. In : Psoriasis (Roenigk HH, Maibach HI, eds 2nd edn. New York : Dekker, 1991 83 6.
192. Alexandroff AB, Novitskaya ES, Armstrong DJ. Psoriasis as a multisystem inflammatory disease. In : Trends in Dermatology Research (Columbus F, ed). Hauppauge, NY : Nova Science, 2010 (in press).
193. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007 56 : 2905 2912.
194. Prodanovich S, Ma F, Taylor JR et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 52 : 262 267.
195. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004 110 : 1774 1779.
196. Kumar N, Armstrong DJ. Cardiovascular disease - the silent killer in rheumatoid arthritis. Clin Med 2008 8 : 384 387.
197. Raftery G, Armstrong DJ. 'Non solum.sed etiam': added cardiac benefits of TNF alpha blockade in rheumatoid arthritis. J R Coll Physicians Edin 2008 38 : 108 111.
198. Chiu LS, Ho MS, Hsu LY et al. Prevalence and molecular characteristics of Staphylococcus aureus isolates colonizing patients with atopic dermatitis and their close contacts in Singapore. Br J Dermatol 2009 160 : 965 971.
199. Warner JA, McGirt LY, Beck LA. Biomarkers of Th2 polarity are predictive of staphylococcal colonization in subjects with atopic dermatitis. Br J Dermatol 2009 160 : 183 185.
200. Durupt F, Mayor L, Bes M et al. Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br J Dermatol 2007 157 : 1161 1167.
201. Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2008 159 : 105 112.
202. Kedzierska A, Kapinska-Mrowiecka M, Czubak-Macugowska M et al. Susceptibility testing and resistance phenotype detection in Staphylococcus aureus strains isolated from patients with atopic dermatitis, with apparent and recurrent skin colonization. Br J Dermatol 2008 159 : 1290 1299.
203. Maltezou HC, Giamarellou H. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents 2006 27 : 87 96.
204. Halem M, Trent J, Green J et al. Community-acquired methicillin resistant Staphylococcus aureus skin infection. Semin Cutan Med Surg 2006 25 : 68 71.
205. Alexandroff AB, Perera N, Gothard P et al. Community acquired MRSA. Expert opinion. MIMS Dermatol 2008 4 : 14.
206. Diep BA, Palazzolo-Ballance AM, Tattevin P et al. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS ONE 2008 3 : e3198.
207. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003 36 : 131 139.
208. Holmes A, Ganner M, McGuane S et al. Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease. J Clin Microbiol 2005 43 : 2384 2390.
209. Aramburu C, Harbarth S, Liassine N et al. Community-acquired methicillin-resistant Staphylococcus aureus in Switzerland: first surveillance report. Euro Surveill 2006 11 : 42 3.
210. Lee YT, Lin JC, Wang NC et al. Necrotizing fasciitis in a medical center in northern Taiwan: emergence of methicillin-resistant Staphylococcus aureus in the community. J Microbiol Immunol Infect 2007 40 : 335 341.
211. Millar BC, Prendergast BD, Moore JE. Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis. J Antimicrob Chemother 2008 61 : 1 7.
212. Goldstein SM, Shelsta HN. Community-acquired methicillin-resistant Staphylococcus aureus periorbital cellulitis: a problem here to stay. Ophthal Plast Reconstr Surg 2009 25 : 77.
213. Sifri CD, Park J, Helm GA et al. Fatal brain abscess due to community-associated methicillin-resistant Staphylococcus aureus strain USA300. Clin Infect Dis 2007 45 : e113 17.
214. Gonzalez BE, Martinez-Aguilar G, Hulten KG et al. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005 115 : 642 648.
215. Gonzalez BE, Hulten KG, Dishop MK et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005 41 : 583 590.
216. Chambers HF, Moellering RC Jr., Kamitsuka P. Clinical decisions. Management of skin and soft-tissue infection. N Engl J Med 2008 359 : 1063 1067.
217. Dial S, Kezouh A, Dascal A et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008 179 : 767 772.
218. Raksha MP, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol 2008 74 : 80.
219. Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008 18 : 99 107.
220. Friedrich AW, Daniels-Haardt I, Kock R et al. EUREGIO MRSA-net Twente/Munsterland - a Dutch-German cross-border network for the prevention and control of infections caused by methicillin-resistant Staphylococcus aureus. Euro Surveill 2008 13. pii : 18965.
221. Vos MC, Ott A, Verbrugh HA. Successful search-and-destroy policy for methicillin-resistant Staphylococcus aureus in The Netherlands. J Clin Microbiol 2005 43 : 2034 2035.
222. Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003 4 : CD003340.
223. Chow A, Wilder-Smith EP. Effect of transdermal botulinum toxin on sweat secretion in subjects with idiopathic palmar hyperhidrosis. Br J Dermatol 2009 160 : 721 722.
224. Kim WO, Kil HK, Yoon KB et al. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol 2008 158 : 1094 1097.
225. Bechara FG, Sand M, Tomi NS et al. Repeat liposuction-curettage treatment of axillary hyperhidrosis is safe and effective. Br J Dermatol 2007 157 : 739 743.
226. Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol 2007 157 : 118 121.
227. Benohanian A. Needle-free anaesthesia prior to botulinum toxin type A injection treatment of palmar and plantar hyperhidrosis. Br J Dermatol 2007 156 : 593 596.
228. Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 2007 156 : 986 989.
229. Bechara FG, Altmeyer P, Sand M et al. Surgical treatment of axillary hyperhidrosis. Br J Dermatol 2007 156 : 398 399.
230. Balabanova M, Popova L, Tchipeva R. Dyes in dermatology. Clin Dermatol 2003 21 : 2 6.
231. Tan HH, Tan AW, Barkham T et al. Community-based study of acne vulgaris in adolescents in Singapore. Br J Dermatol 2007 157 : 547 551.
232. Benton EC, Kerr OA, Fisher A et al. The changing face of dermatological practice: 25 years' experience. Br J Dermatol 2008 159 : 413 418.
233. Walsh SA, Holme SA. Acne successfully treated with acitretin in a patient with peanut allergy. Reply. Br J Dermatol 2008 159 : 1208 1209.
234. Abdel Fattah NS, Shaheen MA, Ebrahim AA et al. Tissue and blood superoxide dismutase activities and malondialdehyde levels in different clinical severities of acne vulgaris. Br J Dermatol 2008 159 : 1086 1091.
235. Vora S, Ovhal A, Jerajani H et al. Correlation of facial sebum to serum insulin-like growth factor-1 in patients with acne. Br J Dermatol 2008 159 : 990 991.
236. Langner A, Chu A, Goulden V et al. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol 2008 158 : 122 129.
237. Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol 2008 158 : 208 216.
238. Azoulay L, Oraichi D, Berard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol 2007 157 : 1240 1248.
239. Sladden MJ, Clarke PJ, Mitchell B. Infliximab-induced acne: report of a third case. Br J Dermatol 2008 158 : 172.
240. Mavilia L, Malara G, Moretti G et al. Photodynamic therapy of acne using methyl aminolaevulinate diluted to 4% together with low doses of red light. Br J Dermatol 2007 157 : 810 811.
241. Charakida A, Charakida M, Chu AC. Double-blind, randomized, placebo-controlled study of a lotion containing triethyl citrate and ethyl linoleate in the treatment of acne vulgaris. Br J Dermatol 2007 157 : 569 574.
242. Verfaille CJ, Coel M, Boersma IH et al. Oral R115866 in the treatment of moderate to severe facial acne vulgaris: an exploratory study. Br J Dermatol 2007 157 : 122 126.
243. Wilcox HE, Farrar MD, Cunliffe WJ et al. Resolution of inflammatory acne vulgaris may involve regulation of CD4+ T-cell responses to Propionibacterium acnes. Br J Dermatol 2007 156 : 460 465.
244. Mourelatos K, Eady EA, Cunliffe WJ et al. Temporal changes in sebum excretion and propionibacterial colonization in preadolescent children with and without acne. Br J Dermatol 2007 156 : 22 31.
245. Hamilton FL, Car J, Lyons C et al. Laser and other light therapies for the treatment of acne vulgaris: systematic review. Br J Dermatol 2009 160 : 1273 1285.
246. Taylor MN, Gonzalez ML. The practicalities of photodynamic therapy in acne vulgaris. Br J Dermatol 2009 160 : 1140 1148.
247. Ganceviciene R, Graziene V, Fimmel S et al. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol 2009 160 : 345 352.
248. Barratt H, Hamilton F, Car J et al. Outcome measures in acne vulgaris: systematic review. Br J Dermatol 2009 160 : 132 136.
249. Layton AM, Dreno B, Gollnick H et al. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol 2009 160 : 217 218.
250. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008 159 : 1245 1266.
251. Brazzelli V, Larizza D, Muzio F et al. Low frequency of acne vulgaris in adolescent girls and women with Turner's syndrome: a clinical, genetic and hormonal study of 65 patients. Br J Dermatol 2008 159 : 1209 1211.
252. Burkhart CG, Burkhart CN. The chemistry and synergy of benzoyl peroxide with clindamycin. Br J Dermatol 2008 159 : 480 481.
253. Laing ME, Murphy GM, Buckley CC. Acne successfully treated with acitretin in a patient with peanut allergy. Br J Dermatol 2008 159 : 250 251.
254. Melnik BC, Vakilzadeh F, Aslanidis C et al. Unilateral segmental acneiform naevus: a model disorder towards understanding fibroblast growth factor receptor 2 function in acne? Br J Dermatol 2008 158 : 1397 1399.
255. Taibjee SM, Charles-Holmes R. Pitfalls of prescribing acne therapies including isotretinoin for pilots. Br J Dermatol 2008 158 : 653 655.
256. Logan AC. Linoleic and linolenic acids and acne vulgaris. Br J Dermatol 2008 158 : 201 202.
257. Cordain L, Lindeberg S, Hurtado M et al. Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002 138 : 1584 1590.
258. Danby FW. Acne and milk, the diet myth, and beyond. J Am Acad Dermatol 2005 52 : 360 362.
259. Ginther OJ, Nuti L, Wentworth BC et al. Progesterone concentration in milk and blood during pregnancy in cows. Proc Soc Exp Biol Med 1974 146 : 354 357.
260. Heap RB, Linzell JL, Laing JA. Proceedings. Pregnancy diagnosis in cows: use of progestagen concentration in milk. Vet Rec 1974 94 : 160.
261. Hoffmann B, Hamburger R, Karg H. Natural occurrence of progesterone in commercial milk products (author's transl). Z Lebensm Unters Forsch 1975 158 : 257 259.
262. Ginther OJ, Nuti LC, Garcia MC et al. Factors affecting progesterone concentration in cow's milk and dairy products. J Anim Sci 1976 42 : 155 159.